Iambic Therapeutics, Inc. (IAM) stock analysis
IAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$15.38+0.61 (+4.09%)
Close on Nov 11, 2026Market cap –P/E –Yield –
Analysis
Not enough annual history yet
Analysis needs at least two fiscal years of reported financials for Iambic Therapeutics.
See a number that looks wrong?